Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. Co. is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. We show 51 historical shares outstanding datapoints in our SUPN shares outstanding history coverage, used to compute SUPN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SUPN market cap history over the course of time is important for investors
interested in comparing SUPN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SUPN versus a peer is one thing; comparing
SUPN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SUPN can fluctuate over the course of history.
With this page we aim to empower investors researching SUPN by allowing them to research the SUPN market cap history. |
Free SUPN Email Alerts:
Video: The Importance of Market Cap
